Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug fabhalta tracked in kidney disease patients

NCT ID NCT07156149

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study will follow 50 people with C3 glomerulopathy, a rare kidney disease, who are taking the drug Fabhalta. Researchers want to see how safe the drug is and how well it works in everyday clinical settings. They will track infections, side effects, and kidney function over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fabhalta (iptacopan)
What this could lead to
If successful, this could confirm that Fabhalta is a safe and effective treatment option for managing C3 glomerulopathy in everyday medical practice.
What could go wrong
This is an observational study with no control group, so results may not prove cause and effect. The small size (50 patients) limits how broadly findings can be applied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

complement 3 glomerulopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C3 GLOMERULOPATHY

Contacts and locations

Locations

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 466-8650, Japan

  • Novartis Investigative Site

    Toyoake, Aichi-ken, 4701192, Japan

  • Novartis Investigative Site

    Hirosaki, Aomori, 0368563, Japan

  • Novartis Investigative Site

    Chiba, Chiba, 2608677, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, 810-8563, Japan

  • Novartis Investigative Site

    Kitakyushu, Fukuoka, 8028555, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 0040041, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 0608604, Japan

  • Novartis Investigative Site

    Tsukuba, Ibaraki, 3058576, Japan

  • Novartis Investigative Site

    Komatsu, Ishikawa-ken, 923-0961, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 231-8682, Japan

  • Novartis Investigative Site

    Tosa-gun, Kyoto, 629-2261, Japan

  • Novartis Investigative Site

    Tsu, Mie-ken, 514-8507, Japan

  • Novartis Investigative Site

    Nagasaki, Nagasaki, 852-8501, Japan

  • Novartis Investigative Site

    Suita, Osaka, 565-0871, Japan

  • Novartis Investigative Site

    Takatsuki, Osaka, 5698686, Japan

  • Novartis Investigative Site

    Kusatsu, Shiga, 525-8585, Japan

  • Novartis Investigative Site

    Ohtsu, Shiga, 5202192, Japan

  • Novartis Investigative Site

    Shizuoka, Shizuoka, 420-8527, Japan

  • Novartis Investigative Site

    Shimotsuga Gun, Tochigi, 3210293, Japan

  • Novartis Investigative Site

    Tokushima, Tokushima, 7708503, Japan

  • Novartis Investigative Site

    Bunkyo-ku, Tokyo, 1138519, Japan

  • Novartis Investigative Site

    Fuchū, Tokyo, 1838561, Japan

  • Novartis Investigative Site

    Nakano City, Tokyo, 164-8607, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 1628666, Japan

  • Novartis Investigative Site

    Hiroshima, 7348530, Japan

  • Novartis Investigative Site

    Ishikawa, 9208641, Japan

  • Novartis Investigative Site

    Nara, 630-8581, Japan

  • Novartis Investigative Site

    Wakayama, 640-8558, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.